GENERATING HEALTH TECHNOLOGY ASSESSMENT EVIDENCE FOR RARE DISEASES. (19th November 2014)

• Record Type: Journal Article
• Authors: Facey, Karen; Granados, Alicia; Guyatt, Gordon; Kent, Alastair; Shah, Nilay; van der Wilt, Gert Jan; Wong-Rieger, Durhane
• Is Part Of: International journal of technology assessment in health care. Volume30:Number 4(2014:Oct.)
• Page Start: 416
• Page End: 422
• Publication Date: 2014-11-19
• Subjects: Medical technology -- Periodicals; Technology assessment -- Periodicals; 610.28
• DOI: 10.1017/S0266462314000464
• Languages: English
• ISSNs: 0266-4623

Abstract

<abstract abstract-type="normal"> <title> <x content-type="archive" xml:space="preserve">Abstract</x> </title> <p> <bold>Objectives:</bold> Rare diseases are often heterogeneous in their progression and response to treatment, with only a small population for study. This provides challenges for evidence generation to support HTA, so novel research methods are required.</p> <p> <bold>Methods:</bold> Discussion with an expert panel was augmented with references and case studies to explore robust approaches for HTA evidence generation for rare disease treatments.</p> <p> <bold>Results:</bold> Traditional RCTs can be modified using sequential, three-stage or adaptive designs to gain more power from a small patient population or to focus trial design. However, such designs need to maintain important design aspects such as randomization and blinding and be analyzed to take account of the multiple analyses performed. N-of-1 trials use within-patient randomization to test repeat periods of treatment and control until a response is clear. Such trials could be particularly valuable for rare diseases and when prospectively planned across several patients and analyzed using Bayesian techniques, a population effect can be estimated that might be of value to HTA. When the optimal outcome is unclear in a rare disease, disease specific patient reported outcomes can elucidate impacts on patients' functioning and wellbeing. Likewise, qualitative research can be used to elicit patients' perspectives, with just a small number of patients.</p> <p> <bold>Conclusions:</bold> International consensus is needed on ways to improve evidence collection and assessment of technologies for rare diseases, which recognize the value of novel study designs and analyses in a setting where the outcomes and effects of importance are yet to be agreed.</p> </abstract>